Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet–Induced Obese Mice
Top Cited Papers
- 31 March 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (6), 1292-1305
- https://doi.org/10.2337/db19-0991
Abstract
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have favorable cardiovascular outcomes in patients with diabetes. However, whether SGLT2i can improve obesity-related cardiac dysfunction is unknown. Sestrin2 is a novel stress-inducible protein that regulates AMPK–mammalian target of rapamycin (mTOR) and suppresses oxidative damage. The aim of this study was to determine whether empagliflozin (EMPA) improves obesity-related cardiac dysfunction via regulating Sestrin2-mediated pathways in diet-induced obesity. C57BL/6J mice and Sestrin2 knockout mice were fed a high-fat diet (HFD) for 12 weeks and then treated with or without EMPA (10 mg/kg) for 8 weeks. Treating HFD-fed C57BL/6J mice with EMPA reduced body weight and whole-body fat and improved metabolic disorders. Furthermore, EMPA improved myocardial hypertrophy/fibrosis and cardiac function and reduced cardiac fat accumulation and mitochondrial injury. Additionally, EMPA significantly augmented Sestrin2 levels and increased AMPK and endothelial nitric oxide synthase phosphorylation, but inhibited Akt and mTOR phosphorylation. These beneficial effects were partially attenuated in HFD-fed Sestrin2 knockout mice. Intriguingly, EMPA treatment enhanced the Nrf2/HO-1–mediated oxidative stress response, suggesting antioxidant and anti-inflammatory activity. Thus, EMPA improved obesity-related cardiac dysfunction via regulating Sestrin2-mediated AMPK-mTOR signaling and maintaining redox homeostasis. These findings provide a novel mechanism for the cardiovascular protection of SGLT2i in obesity.Keywords
Funding Information
- American Diabetes Association (1-17-IBS-296)
This publication has 47 references indexed in Scilit:
- MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK PathwayCirculation Research, 2015
- Overnutrition, mTOR signaling, and cardiovascular diseasesAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2014
- Sestrin2 promotes LKB1‐mediated AMPK activation in the ischemic heartThe FASEB Journal, 2014
- AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1Archives of Biochemistry and Biophysics, 2014
- Sestrins Activate Nrf2 by Promoting p62-Dependent Autophagic Degradation of Keap1 and Prevent Oxidative Liver DamageCell Metabolism, 2013
- High free fatty acids level related with cardiac dysfunction in obese ratsDiabetes Research and Clinical Practice, 2012
- Obesity and cardiovascular disease: From pathophysiology to risk stratificationInternational Journal of Cardiology, 2010
- p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR SignalingCell, 2008
- Akt1 in the cardiovascular system: friend or foe?JCI Insight, 2005
- Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophyCanadian Journal of Physiology and Pharmacology, 2005